12:41 PM EDT, 06/20/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday it will "continue to pursue legal remedies" against medical spas, wellness centers and other entities for selling products that claim to contain tirzepatide, the active ingredient in its diabetes drugs Mounjaro and Zepbound.

The pharmaceutical company filed six separate lawsuits in the courts of Ohio, Texas, Hawaii and the District of Columbia, Reuters reported Thursday.

Lilly alleged these entities falsely claim their products are approved by the US Food and Drug Administration.

The company warned that untested or unsafe compounded tirzepatide poses risks to patients. It expressed concerns over the growing number of online sales and social media posts involving counterfeit versions of its drug.

Price: 895.50, Change: +4.04, Percent Change: +0.45